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Abstract
In recent years, we have witnessed many transitions in healthcare systems around the globe. For example, population expansion and ageing,
and the human immunodeﬁciency virus (HIV)-AIDS epidemics, have exerted pressure to decentralize the practice of healthcare outside of
traditional settings to bring care to those in need. Upstream of patient management, diagnosis is aimed at adequately orienting medical deci-
sions, and considerable efforts have been made to make this process faster and more efﬁcient. However, there are several diseases and
medical conditions that may/will beneﬁt from technologies and tests that can be performed closer to the patient, at the point of care or
even in the home. In this review, and in light of the paradox that technology and assay developers and healthcare ofﬁcials must take into
consideration for advancing human health in developed and developing countries, we present an overview of rapid diagnosis of infectious
diseases at the point of care and of technologies that may contribute to enhancement of the worldwide point-of-care testing market.
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Introduction
Diagnostic microbiology, and to a certain extent personalized
medicine, is the medical process by which potentially infected
biological samples are evaluated to identify the microorgan-
ism(s) associated with an infection and determine, if neces-
sary, its antimicrobial drug resistance and/or toxin
production proﬁles, to guide appropriate management of the
patient. The need to rapidly identify microbial pathogens has
guided the evolution of the discipline by the convergence of a
wide array of biochemical, immunological, optical and molec-
ular biology methods, from an original point that can be
traced as far back as 1676, when Antonie von Leuwenhoek
recorded the ﬁrst observation of minute living things, which
he simply called animalcules. This observation, made some
200 years before the discoveries of Pasteur and the infectious
diseases postulates of Koch, is considered to be the ﬁrst
milestone in the history of diagnostic microbiology [1].
Infectious diseases, which annually claim about 14 million
lives i.e. c. 25% of the more or less 56 million deaths
recorded worldwide, are still the primary cause of mortality
[2,3]. In the USA, for example, despite major advances in
public health and antimicrobial chemotherapy that signiﬁ-
cantly contributed to an increase in the lifespan of the
human population in the 20th century, it was determined
that, after a sharp decline in infectious disease mortality,
from 797 to 36 deaths per 100 000, between 1900 and
1980, the mortality rate increased to 63 per 100 000 in
1995, and then fell back to 59 per 100 000 in 1996 [4]. The
variation observed between 1980 and 1995, in part attri-
buted to the emergence of AIDS, illustrates the dynamic nat-
ure of infectious disease and exempliﬁes the vulnerability of
populations to emerging diseases, as seen during the H1N1
inﬂuenza pandemic of 2009.
The challenges of infectious diseases diagnosis
By the very nature of the causal agents, their mode of dis-
semination, and the life-threatening host reactions that they
may elicit, infectious diseases are clearly distinct from most
genetic diseases and chronic conditions, as the appropriate
course of medical action to isolate and/or treat the patient
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should be governed by a major need for speed, to: (i) identify
the microbe, as this vital information will guide the ﬁrst few
critical hours of patient management; (ii) determine its anti-
microbial susceptibility or toxin production proﬁle, to esti-
mate the appropriateness of the treatment and modify it if
necessary; and and (iii) evaluate biomarkers of drug metabo-
lism (pharmacogenetics) or susceptibility to infection (immu-
nogenetics) in the context of an integrated personalized
medicine approach [1,5,6]. In a life-threatening situation such
as sepsis, the critical time window for appropriate manage-
ment is estimated to be less than 6 h, with every hour
gained in the initiation of proper antimicrobial therapy signiﬁ-
cantly increasing the probability of the patient surviving the
infection [7,8].
Clinical microbiology has not beneﬁted as extensively as
biochemistry, haematology and radiology from the techno-
logical progress that has decreased the complexity of
procedures and, hence, the turn-around time for diagnosis
(Fig. 1). In the 1960s and 1970s, reassured by the availability
of an expanding spectrum of antimicrobial agents, physicians
embraced an empirical approach to the management of many
infectious diseases, favouring overuse of antibiotics, a selec-
tion process that contributed to an increase in antimicrobial
resistance and to the emergence of hospital-acquired infec-
tions. In a recent study of the impact of antiviral therapy
against inﬂuenza, McGeer et al. [9] reported that 89% of
patients with a (prospectively) conﬁrmed inﬂuenza diagnosis
received antibacterial therapy upon admission. Such a blatant
example of infectious disease mismanagement supports the
pressing need for fast and adequate infectious disease diag-
nostic procedures. Now, at the beginning of the 21st cen-
tury, a high proportion of diagnostic tests are still performed
according to methodologies pioneered by Pasteur at the
end of the 19th century, i.e. methods based on culture,
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FIG. 1. The need for speed in diagnostic microbiology. From patient admission to the making of decisions orienting the management or treat-
ment, gains in time to delivery of results may translate into a better healthcare system. For a life-threatening syndrome such as sepsis, rapid
identiﬁcation of the microbial pathogen in less than 6 h is especially critical for the proper management and treatment of a patient, resulting in
lower morbidity and mortality.
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microscopy, and serology, although rapid molecular biology-
based technologies are gradually penetrating the ﬁeld
[1,5,6,10].
Point-of-care (POC) diagnosis
Ehrmeyer and Laessig [11] have deﬁned POC testing as
patient specimens being assayed at or near the patient, with the
assumption that test results will be available instantly or in a very
short time frame, to assist care-givers with immediate diagnosis
and/or clinical intervention. Theoretically, POC testing has the
potential to deliver analytical results more rapidly, in an effort
to generate an appropriate diagnosis, accelerate patient man-
agement, and provide adequate treatment, if necessary. How-
ever, the realization of this potential is hampered by issues
concerning test reliability, performance, quality, cost, regula-
tory approval, documentation, and connectivity [12–16].
The current market for POC testing, largely dominated by
glucose, cardiac and pregnancy testing, is the fastest-growing
segment of a worldwide clinical diagnostic market evaluated
as being US$30 billion in 2005, representing approximately
36% of the total [11]. On the assumption of a compounded
annual growth rate of 9%, and not taking into account the
penetration of new technologies and the prediction that
POC test use in clinical diagnosis might soon reach 50%, the
overall clinical diagnostics market could be in excess of
US$50 billion in 2011, with POC testing grossing annual rev-
enues ranging from US$18 billion to US$25 billion [17,18].
For infectious diseases, the expanding spectrum of (com-
mercially) available POC tests essentially consists of rapid
diagnostic tests (RDTs), based on direct microscopy, or anti-
body-based recognition methods, such as agglutination,
enzyme-linked immunosorbent assays, optical immunoassays,
and lateral-ﬂow immunochromatographic tests [15,19,20].
There is not, as yet, a real nucleic acid-based POC test. The
most widely tested infections or microorganisms include bac-
terial vaginosis, Borrelia burgdorferi, Candida vulvovaginitis,
Chlamydia trachomatis, Clostridium difﬁcile, Cryptosporidium par-
vum, diarrhoeal diseases, Entamoeba histolytica/dispar, lympha-
tic ﬁlariasis, Giardia intestinalis, human immunodeﬁciency virus
(HIV), human papillomavirus (HPV), Helicobacter pylori, inﬂu-
enza A/B virus, lower respiratory tract infections, malaria,
Neisseria gonorrhoeae, Streptococcus agalactiae, Streptococcus
pyogenes, Treponema pallidum, and Trichomonas vaginalis
[19,21–29]. A regularly updated list of Clinical Laboratory
Improvement Amendments (CLIA)-waived tests can be
uploaded from http://www.cms.hhs.gov/CLIA/downloads/
waivetbl.pdf.
Notwithstanding the fact that many RDTs have been
waived by CLIA, CE-marked, or approved by the US Food
and Drug Administration (FDA), they exhibit many weak-
nesses in terms of fabrication, stability of components, and
operation, and are more prone to errors, the principal con-
founding factor being the technical skill level of the individual
handling the test [13–15,17,21,30–32]. In resource-limited
settings, however, the implementation of RDTs has many
advantages over alternative approaches such as syndromic
management [28]. Finally, many RDTs offer a level of perfor-
mance (sensitivity, speciﬁcity, and negative and positive pre-
dictive values) that is inferior to that of molecular diagnostic
tests performed by highly skilled personnel working in a
quality-controlled environment.
Technologies for Improving POC Diagnosis
of Infectious Diseases
POC diagnosis of infectious diseases is currently limited to
rapid microscopy or immunochromatography (lateral ﬂow,
dipstick, or card) tests, as no DNA-based test has yet
achieved POC status. Relatively simple in principle, these
tests have variable levels of performance that are dependent
on the nature of the target microbe(s), the robustness of
components and reagents, and the technical skill level of the
test handler. In this section of the article, we examine recent
technological progress that could serve to improve POC
tests and elevate them to a performance level commensurate
with the ASSURED characteristics of an ideal diagnostic test,
i.e. Affordable, Sensitive, Speciﬁc, User-friendly, Rapid, Equip-
ment-free, and Delivered to those in need [33,34]. In fact,
we believe that these criteria should be applied to as many
diagnostic technologies and tests as possible, to maximize
their applicability in developing and developed countries.
Microscopy-based methods for direct detection of microbial
particles
Observing a microorganism in an infected sample or tissue
constitutes one of Koch’s postulates, and microscopy has
been an invaluable tool for this purpose. The direct and spe-
ciﬁc detection of microbial particles in clinical samples repre-
sents a very direct and fast route towards useful diagnostic
answers, as it circumvents some of the sample preparation
steps needed to extract microbe-speciﬁc components and
microbes. Direct detection of pathogens by microscopy, in
its most simple form, can be achieved by histological staining,
but more speciﬁc immunological or (peptide) nucleic acid
probes can be used as part of microscopy-based methods
[35]. With or without the use of histological stains, the
direct detection of pathogens in slide smears remains an
inexpensive method for the diagnosis of many diseases
(tuberculosis, malaria, etc.), although the procedures are
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lacking in terms of sensitivity and speciﬁcity, and this is fur-
ther complicated by the expertise level of test performers
[36]. Misdiagnosis of tuberculosis or malaria in regions lack-
ing good microscopy services is hampering efforts to control
the diseases, warranting efforts to develop more accurate
and speciﬁc, but affordable, tests [37,38]. Conventional
microscopy-based methods may be improved by the incor-
poration of ﬂuorescent immunological or (peptide) nucleic
acid probes [35]. Electron microscopy is certainly not a tech-
nology that can be used at the point of care, but it possesses
invaluable attributes for the rapid diagnosis of (unculturable)
pathogens such as viruses in emergent situations [39].
Recovery, concentration and detection of microbial
particles
A basic operational characteristic underlying immunochroma-
tography (lateral ﬂow) methods is the concentration of
microbial particles or antigens on a separation nitrocellulose
strip by the use of conventional antibodies. However, anti-
bodies are macromolecules that are highly susceptible to
thermal inactivation, and the handling of RDTs in tropical
countries must be performed with procedures that minimize
unnecessary exposure to humidity and heat. Theoretically
more tolerant to thermal inactivation than proteins, apta-
mers are nucleic acid molecules that can be selected in vitro
for their ability to bind to ultrastructural features of
microbes with high afﬁnity, and could be included in RDTs in
the future [40–42].
New generations of immunoassays
Antigen–antibody interactions, which are widely exploited in
biomedical diagnostics, constitute the core of most commer-
cially available RDTs, mainly lateral ﬂow assays. Although
they are simple in appearance, immunochromatographic
methods do require a certain level of sophistication, for at
least four important reasons, as follows.
Chromatographic support. The support for most lateral ﬂow-
based assays principally consists of nitrocellulose strips
encased in plastic or cardboard. Recently, Kammila et al. [43]
published the concept of an immunoswab, a simple platform
combining sample collection and immunological testing that
could signiﬁcantly facilitate and accelerate the diagnostic pro-
cess, especially at the point of care. A number of difﬁculties
with the nitrocellulose wick have been identiﬁed by Bell et al.
[21], and to circumvent these, another conﬁguration advance
could be provided by the marketing of Ortho Clinical Diag-
nostics’ Forecast Technology (formerly 4castchip of A˚mic
AB), a silica-based microfabricated platform for performing
sensitive immunoassays at the point of care with ﬂuores-
cence detection for signal generation (Mendel-Hartvig, 41st
Annual Oak Ridge Conference, 2009, Session I presentation).
Molecular recognition. Most rapid POC diagnostic tests rely
on antibodies, proteins that have a limited tolerance to
stressful environmental conditions and sometimes lack speci-
ﬁcity towards certain targets. For the detection of disease
biomarkers in environmentally demanding areas, aptamer
sensors constitute an interesting, but underexploited, alter-
native [40–42,44]. Similar to the case with antibodies, it was
demonstrated that the SELEX process can be tailored to ﬁt
the biosensor design, such that aptamers that are more efﬁ-
cient for array-like detection can be selected, thereby open-
ing the ﬁeld for lateral ﬂow-based detection with an
alternative method of molecular recognition [45].
Detection schemes. Unless analytes are present in sufﬁciently
high concentration, RDTs may lack sensitivity when conven-
tional colorimetric detection is used. Thus, to increase the
usefulness of the technology, new signal ampliﬁcation tech-
nologies and semiquantitative approaches should be evalu-
ated for their robustness and performance, especially in the
context of low-resource settings [46].
Multiparametric detection. Enabling multiple detection in an
immunoassay format is another means of reducing cost, by
reducing the number of tests required to determine the
microbial content of a complex sample. For eventual POC
applications, antibody arrays fabricated on supports such as a
porous nitrocellulose membrane or at the tip of an optic
ﬁbre have been recently reported [47–49].
Faster and/or Multiparametric POC
Diagnosis of Infectious Diseases
Diagnostic microbiology (and the health of patients) will
greatly beneﬁt from any technological advance that will: (i)
make the time-scale of testing of clinical samples similar to
that of biochemistry, haematology, or radiology, but with a
sensitivity and speciﬁcity superior to those of immunology-
based RDTs; and (ii) enable diagnosis to be performed ever
closer to the patient (Fig. 1). It is our belief that molecular
nucleic acid-based diagnostic approaches constitute the prin-
cipal tools that can alleviate the need to culture and provide
tests enabling the multiparametric identiﬁcation of a micro-
bial pathogen from a spectrum of microorganisms associated
with a syndromic infection, e.g. sepsis or respiratory tract
infection. For the time being, there is no DNA-based POC
test available on the market, as the conﬁgurations of most
CMI Bissonnette and Bergeron Current and future technologies for POC diagnosis of infections 1047
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1044–1053
molecular ampliﬁcation technologies are incompatible with
POC diagnosis, for reasons of staff technical qualiﬁcations,
assay cost, energy, and regulatory compliance requirements.
However, in the context of near-POC testing, a specialized
(satellite or physician ofﬁce) laboratory could offer a well-
designed menu of high-quality tests and deliver diagnostic
results within the optimal time frame for managing infectious
diseases [50,51].
Molecular ampliﬁcation
Since the pioneering BD GeneOhm StrepB (formerly IDI-
StrepB) real-time PCR test was granted FDA approval in
2002 for the in vitro rapid (less than 1 h) diagnosis of S. aga-
lactiae directly from a clinical sample [52], it has been fol-
lowed by many others on similar technological platforms
(see Association for Molecular Pathology website at http://
www.amp.org/ID/infectious.htm). Generally, real-time PCR
tests concentrate on limited number of genetic targets, but
this changed when Roche Molecular Diagnostics introduced
the LightCycler SeptiFast test, a multiplex assay for detecting
25 blood-borne pathogens in patients with septicaemia in
less than 6 h. Although SeptiFast has some weaknesses, this
diagnostic procedure is expected to foster a new generation
of tests that could enhance evidence-based treatment for
critically ill patients [53–55].
For implementation at the point of care or in low-
resource settings, however, developers must take into
account the ASSURED criteria delineated by Mabey et al.
[33] and seriously consider future directions, such as isother-
mal ampliﬁcation, that could partly relieve the requirement
for an artiﬁcial energy source to adequately drive the bio-
chemical process, or simpler device or instrument platforms.
Recent examples of efforts include the simple ampliﬁcation-
based assay for the detection of HIV-1 in a dipstick format,
helicase-dependent ampliﬁcation, and loop-mediated isother-
mal ampliﬁcation [56–58]. Helicase-dependent ampliﬁcation
and loop-mediated isothermal ampliﬁcation have been
recently implemented on microﬂuidic chip platforms [59,60].
Array-based detection of nucleic acids
For the multiparametric detection and identiﬁcation of the
microorganisms present in a (potentially infected) biological
sample, the nucleic acid-based broad-range PCR ampliﬁca-
tion of genes conserved in evolution (e.g. 16S rDNA),
complemented by the additional information generated by
bidimensional or tridimensional array-based discrimination of
single-nucleotide polymorphisms, may translate into diagnos-
tic tools that are applicable to a particular infection or syn-
drome [61]. For example, a test of this kind for diagnosing
sepsis, including a microarray covering a comprehensive
microbial panel for testing blood samples or positive blood
cultures, could be performed by a satellite laboratory for fas-
ter identiﬁcation of disease-associated microbe(s) following
broad-range PCR.
Integrated ﬂuidic lab-on-a-chip devices for molecular
diagnostics
Microﬂuidics is a rapidly advancing ﬁeld of biomedical sys-
tems engineering that has great potential for POC diagnosis.
The lab-on-a-chip concept consists in the design and devel-
opment of microfabricated integrated systems incorporating
the analytical power of molecular ampliﬁcation, molecular
hybridization and advanced optical or electrochemical detec-
tion for the rapid identiﬁcation of disease-associated biomar-
kers [62,63]. Indeed, to realize the promise of POC
molecular diagnosis, developers must robustly integrate the
essential steps of a multiparametric diagnostic process in a
two-component system, approved by regulatory authorities,
composed of a disposable microfabricated device, ideally
costing less than $25, operated in a hand-held device or por-
table workstation.
The essential steps to resolve a diagnostic question
addressing the detection, identiﬁcation and possible determi-
nation of the antimicrobial resistance or toxin production of
a particular microorganism associated with a syndromic
infection with multiple potential causes (sepsis, respiratory
tract infection, sexually transmitted infection, etc.) include,
but are not limited to: efﬁcient microﬂuid transfer, sample
preparation, microbial particle concentration and lysis, ana-
lyte (nucleic acid) extraction, concentration and/or puriﬁca-
tion, molecular (isothermal) ampliﬁcation, molecular
hybridization, sensitive detection, and (automated) reporting
[5,6,59,60,62–69].
The ﬁrst technological platform illustrating the feasibility
of the concept is undoubtedly the CLIA-waived GeneXpert
platform of Cepheid, on which several tests for infectious
diseases have been implemented (http://www.cepheid.com/
systems-and-software/genexpert-system/). The microﬂuidic
cartridge of this semi-automated platform couples sample
preparation to real-time PCR for the fast detection of micro-
bial targets. Several other sophisticated devices and ancillary
instruments, such as the VereID Biosystem of Veredus Labo-
ratories (http://www.vereduslabs.com), have been commer-
cialized but have not yet obtained regulatory approval in the
USA.
It is expected that, upon compliance with CLIA regula-
tions [70], many microﬂuidic-based diagnostic systems will
eventually develop marketing niches in specialized satellite
laboratories, but this will be more difﬁcult in resource-limited
settings, where major obstacles to implementation cannot be
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easily resolved: energy-independent actuation mechanisms,
integration of sample preparation and molecular ampliﬁca-
tion, long-term stability of reagents, reliance on colorimetric
detection, etc. [71]. Numerous examples of lab-on-a-chip
device prototypes that are more suitable for POC diagnosis
can be found in the literature [63,64,68,69,72–75], but per-
haps simpler devices, such as ﬁnger-actuated microﬂuidic cas-
settes or paper-based microﬂuidic devices, will be more
adapted to operation in developing countries [75–78].
Molecular Technologies for Accelerating
the Microbial Identiﬁcation Process
It is expected that rapid molecular diagnosis performed at
the point of care will contribute to decreasing the morbidity
and mortality of critically ill patients. However, other tech-
nologies, such as mass spectrometry or newer-generation
DNA sequencing methods derived from advances in biophys-
ics, proteomics, and genomics, can efﬁciently complement
conventional microbiology by accelerating the identiﬁcation
of microorganisms isolated from (blood) culture and more
rapidly provide an appreciation of the potential of antimicro-
bial drug resistance and toxin production.
Mass spectrometry
Mass spectrometry is a powerful analytical method that
enables generation of the proﬁle of ionized macromolecule
fragments generated by a laser, followed by a charge-based
and/or mass-based separation in the time of ﬂight. Fragmenta-
tion of macromolecules is performed either by matrix-assisted
laser desorption/ionization or by electrospray ionization. For
rapid bacterial identiﬁcation in clinical microbiology, mass
spectrometry has been applied to analyse the products derived
from a pure culture, an isolated colony or a positive blood cul-
ture in less than 2 h [79–82]. In the context of conventional
clinical microbiology, mass spectrometry could easily compete
with other bacterial identiﬁcation schemes.
Ultrafast (economical) DNA sequencing
For several years, nucleic acid sequencing and pyrosequenc-
ing have been used to genotype post-PCR amplicons of
genes conserved in evolution, e.g. to provide fast and speciﬁc
identiﬁcation of microbes. The progress in metagenomics
was catalysed by a phenomenal increase in the speed (and a
decrease in the cost) of high-throughput nucleic acid de novo
sequencing and pyrosequencing technologies [83].
Partly stimulated by federally funded initiatives aimed
at realizing the promise of personalized medicine by rapid
identiﬁcation of polymorphisms associated with genetic
disorders, drug metabolism, or immunogenetic susceptibility
to infection [6,84], technology developers are bringing to
market sequencing systems that are gradually bringing the
cost of deciphering the genome of an individual from a few
million dollars to less than ten thousand dollars [85–87].
Similar to the expected penetration of mass spectrometry in
clinical microbiology (specialized satellite laboratories),
newer sequencing technologies have the potential to acceler-
ate the identiﬁcation process for an emerging or unknown
pathogen if the cost of rapid microbial sequencing reaches a
reasonable level. Coupled with powerful bioinformatic tools
for rapid genome assembly, rapid sequencing will probably
distinguish itself from mass spectrometry by its ability to
provide ultrafast determination of the antimicrobial resis-
tance proﬁle of a microbe, including the identiﬁcation of
novel mutations.
Label-free detection methods
The direct and highly sensitive detection of microbial parti-
cles or components is envisaged as a means of reducing the
number of steps of a diagnostic procedure. Opto-mechanical
detection schemes can be used to provide evidence of rec-
ognition of particles or macromolecules by sensor compo-
nents such as nucleic acid (or aptamer) probes, antibodies,
or antigens. Examples include surface plasmon resonance
biosensors, cantilever-based biosensors, and the Young inter-
ferometer [74,88–92].
The promises of nanotechnology and single-molecule
detection
The development of diagnostic processes operating with
components at the nanometre (10)9 m) scale is fast becom-
ing a reality in academic and specialized laboratories. Several
nanoparticle-based detection schemes relying on (paramag-
netic) nanoparticles, nanorods or quantum dots have been
developed for the rapid and sensitive detection of pathogens
(for recent reviews on the topic, see [93–96]), a good exam-
ple in the clinical diagnostics market being the nanoparticle
technology implemented in many FDA-approved Verigene
nucleic acid-based tests from Nanosphere (http://www.nano-
sphere.us). Although the incorporation of functionalized
nanoparticles in immunochromatographic tests may provide
an opportunity to increase the robustness of RDTs, as they
may prove less labile than proteins when used as recognition
components, the development of nano/microﬂuidic diagnostic
devices will still be hampered by the need to incorporate a
highly efﬁcient and economical sample preparation and ana-
lyte puriﬁcation or concentration process capable of deliver-
ing enough target molecules to the sensor area of such a
device.
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The Implementation of POC Diagnosis in
Healthcare
The infrastructure paradox of POC diagnosis
Industrialized and developing countries are quite different mar-
kets for POC technology developers, as the performance and
economic objectives of diagnostic microbiology tests are not
necessarily of the same magnitude. In the most proﬁtable mar-
kets, POC technologies are primarily developed and marketed
for the performance of diagnostic tests outside of core or cen-
tral laboratories, namely in hospitals (emergency ward, inten-
sive-care unit, maternity ward, etc.), in community clinics, in
physician ofﬁces, in pharmacies, and eventually at home [30].
In settings with little or no healthcare infrastructure, how-
ever, there are multiple challenges and constraints that may
render the penetration of tests with increased technology
levels more difﬁcult [33,34,71]. In developing countries,
where (i) laboratory and ﬁnancial resources are scarce, (ii)
healthcare infrastructures and energy sources are limited,
(iii) operational conditions are extreme, and (iv) the frequen-
cies of certain diseases are elevated, the implementation of
rapid POC tests will lead to important socio-economic bene-
ﬁts for populations, whereas the implementation of techno-
logically advanced tests is disadvantaged and may fail.
Implementing molecular diagnostics technologies at the
point of care
In the last 20 years or so, the rise of large-capacity auto-
mated systems for analytical (bio)chemistry and microbiology
has stimulated the emergence of centralized laboratories per-
forming a wide spectrum of diagnostic and genetic analyses.
For many non-life-threatening conditions or chronic diseases,
this model has logistic, operational and economic merits, but
when infectious diseases are considered, the system has seri-
ous ﬂaws in terms of speed, timeliness, and communication of
results. When one considers that the critical window for the
appropriate management of an infection is (conservatively)
<6 h, the wellbeing of a patient, instead of ﬁnancial ﬁgures,
should be the prime concern of healthcare administrations.
Accordingly, we and other experts advocate increased pene-
tration of rapid molecular diagnostics in healthcare where an
integrated personalized medicine strategy could be planned
and initiated [6,32,51,97]. Logistically, en route to bedside
testing, more speciﬁc and sensitive proteomics-based and
genomics-based POC tests for diseases with a low prevalence
should be offered 24/7 in specialized satellite laboratories
[51]. For highly infectious diseases, the European Network
for Infectious Diseases even recommend that analysis of clini-
cal samples be undertaken in biosafety level 3 or 4 infrastruc-
tures [98]. In such controlled environments, a comprehensive
menu of technically more demanding tests could be executed
by skilled laboratory specialists, with the guarantee of better
quality, instead of imposing more stress on clinical staff, espe-
cially when it has been demonstrated that rapid POC tests
are less efﬁcient and more error-prone when handled by
non-laboratory personnel [11,17,32].
Thus, in our opinion, technology and assay developers
should also orient signiﬁcant research and development
efforts towards rapid, but simpler, portable, robust and
affordable assays and devices targeting highly prevalent dis-
eases of developing countries (parasitic diseases, HIV and
other sexually transmitted infections, tuberculosis, etc.),
according to the ASSURED criteria [33,34]. Undoubtedly,
simple (or more complex molecular) RDTs using technolo-
gies with increased innate robustness and better diagnostic
performance will become benchmark products with a better
probability of penetrating prime developed country markets,
such as medical clinics, physician ofﬁces, pharmacies, and
home-based testing. A more global perspective of this vision
is that, in both developing and developed countries, RDTs
performed by minimally trained medical staff may enhance
the cost-effectiveness of screening, and translate into better
management of infections and better targeted treatment. In
these conditions, global health improvement will translate
into socio-economic progress that will eventually permit the
introduction of more elaborate diagnostic technologies in
reference-level facilities, in an effort to develop a technical
and technological capacity for national healthcare systems
[99]. The economic impetus provided by market penetration
of newer rapid (molecular) diagnostic technologies at the
point of care should stimulate the engagement of signiﬁcant
research and development resources to develop more efﬁ-
cient (multiparametric) technologies and tests targeting
neglected infectious diseases. The impact of rapid DNA-
based tests has already been felt, especially in the control
and reduction of hospital-acquired infections caused by meth-
icillin-resistant Staphylococcus aureus [100]. As more tests are
introduced onto the market, clinical practice will change and,
hopefully, the overuse of antibiotics will decrease.
Is Home-based Testing for Infectious
Diseases Possible?
Pregnancy and glucose testing are procedures that have
proven to be relatively efﬁcient and safe for home testing.
However, and as many studies have demonstrated, POC
tests are more prone to errors, and one of the main factors
inﬂuencing their robustness is the skill level of the individual
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performing the test [26]. To address this, the FDA recently
launched the Medical Device Home Use Initiative, to support
the safety and safe use of medical devices in the home [101].
For infectious disease testing, the guidelines of the Initiative
will certainly orient the entrance of RDTs in the home, but
we also believe that technical problems of home-based test-
ing are small in comparison with the important ethical issues
related to the reaction(s), option(s) and action(s) that may
ensue from the visualization of a positive result for an infec-
tion, e.g. HIV [102].
Conclusions
Through the technological advances of the last decade or so,
the process of diagnosing infectious diseases is gradually enter-
ing an era where a physician is in the position to obtain valu-
able identiﬁcation and resistance/toxicity-associated genomic
information on a time-scale comparable to those in other
ﬁelds of diagnostic medicine. However, the need for speed in
diagnostic microbiology is challenged by the current healthcare
core microbiology laboratory system and resistance to the
penetration of molecular diagnostics. Although this revolution
has started, it will require a change in culture without
culture. In the context where the survival of a patient strongly
depends on a diagnostic answer being obtained within 6 h, ide-
ally less than 1 h, the capacity for molecular diagnostic testing
at the point of care is warranted. Although near-POC testing
could be performed in specialized satellite laboratories, we
expect the entrance of true POC molecular testing with inte-
grated disposable devices within 5–10 years.
As most POC rapid immunological tests have levels of
performance that are insufﬁcient for the adequate diagnosis
of infections in low-prevalence settings, we suggest that
molecular diagnostics provide the best platform for impacting
on human health in developed countries. However, in low-
resource settings with high frequencies of diseases such as
HIV infection, tuberculosis, and malaria, RDTs developed
according to the ASSURED criteria may provide a means for
adequately controlling these diseases. There are several pos-
sibilities for improving existing RDT components, and it must
be expected upgraded RDTs will also ﬁnd a niche in devel-
oped countries.
Transparency Declaration
L. Bissonnette declares no conﬂict of interest, and M. G.
Bergeron is the founder and interim CEO of GenePOC Inc.
of Que´bec City, Canada.
References
1. Millar BC, Xu J, Moore JE. Molecular diagnostics of medically impor-
tant infections. Curr Issues Mol Biol 2007; 9: 21–40.
2. Cohen ML. Changing patterns of infectious disease. Nature 2000;
406: 762–767.
3. Global Health Council. Mortality and morbidity of infectious dis-
eases. Available at: http://www.globalhealth.org/infectious_diseases/
mortality_morbidity (last accessed 15 April 2010).
4. Armstrong GL, Conn LA, Pinner RW. Trends in infectious disease
mortality in the United States during the 20th century. JAMA 1999;
281: 61–66.
5. Picard FJ, Bergeron MG. Rapid molecular theranostics in infectious
diseases. Drug Discov Today 2002; 7: 1092–1100.
6. Bissonnette L, Bergeron MG. The next revolution in the molecular
theranostics of infectious diseases: microfabricated systems for per-
sonalized medicine. Expert Rev Mol Diagn 2006; 6: 433–450.
7. Kumar A, Roberts D, Wood KE et al. Duration of hypotension
before initiation of antimicrobial therapy is the critical determinant
of survival in human septic shock. Crit Care Med 2006; 34: 1589–
1596.
8. Dellinger RP, Levy MM, Carlet JM et al. Surviving Sepsis Campaign:
international guidelines for management of severe sepsis and septic
shock: 2008. Crit Care Med 2008; 36: 296–327.
9. McGeer A, Green KA, Plevneshi A et al. Antiviral therapy and out-
comes of inﬂuenza requiring hospitalization in Ontario, Canada. Clin
Infect Dis 2007; 45: 1568–1575.
10. Nissen MD, Sloots TP. Rapid diagnosis in pediatric infectious dis-
eases: the past, the present, and the future. Pediatr Infect Dis 2002;
21: 605–612.
11. Ehrmeyer SS, Laessig RH. Point-of-care testing, medical error, and
patient safety: a 2007 assessment. Clin Chem Lab Med 2007; 45: 766–
773.
12. Jahn UR, Van Aken H. Near-patient testing—point-of-care or point
of costs and convenience? Br J Anaesth 2003; 90: 425–427.
13. Grodzinsky E, Wirehn A-B, Fremner E et al. Point-of-care testing
has a limited effect on time to clinical decision in primary health
care. Scand J Clin Lab Invest 2004; 64: 547–552.
14. Meier FA, Jones BA. Point-of-care testing error—sources and ampli-
ﬁers, taxonomy, prevention strategies, and detection monitors. Arch
Pathol Lab Med 2005; 129: 1262–1267.
15. Nichols JH. Point of care testing. Clin Lab Med 2007; 27: 893–908.
16. Huckle D. Point-of-care diagnostics: an advancing sector with non-
technical issues. Expert Rev Mol Diagn 2008; 8: 679–688.
17. Plebani M. Does POCT reduce the risk of error in laboratory test-
ing? Clin Chim Acta 2009; 404: 59–64.
18. Rajan A, Glorikian H. Point-of-care diagnostics: market trends and
growth drivers. Expert Opin Med Diagn 2009; 3: 1–4.
19. Trevino EA, Weissfeld AS. The case for point-of-care testing in
infectious-disease diagnosis. Clin Microbiol Newsl 2007; 29: 177–179.
20. Overturf GD. CLIA waived testing in infectious diseases. Pediatr
Infect Dis J 2008; 27: 1009–1012.
21. Bell D, Wongsrichanalai C, Barnwell JW. Ensuring quality and access
for malaria diagnosis: how can it be achieved? Nat Rev Microbiol
2006; 4: 682–695.
22. Ryan A, Wilson S, Greenﬁeld S et al. Range of self-tests available to
buy in the United Kingdom: an Internet survey. J Public Health 2006;
28: 370–374.
23. Campbell S. My point-of-care wish list. Point Care 2008; 7: 95–97.
24. Charles PGP. Early diagnosis of lower respiratory tract infections
(point-of-care tests). Curr Opin Pulm Med 2008; 14: 176–182.
25. Murray CK, Gasser RA Jr, Magill AJ, Miller RS. Update on rapid diag-
nostic testing for malaria. Clin Microbiol Rev 2008; 21: 97–110.
CMI Bissonnette and Bergeron Current and future technologies for POC diagnosis of infections 1051
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1044–1053
26. Campbell S, Fedoriw Y. HIV testing near the patient: changing the
face of HIV testing. Clin Lab Med 2009; 29: 491–501.
27. Chappel RJ, Wilson KM, Dax EM. Immunoassays for the diagnosis of
HIV: meeting future needs by enhancing the quality of testing. Future
Microbiol 2009; 4: 963–982.
28. Madhivan P, Krupp K, Hardin J et al. Simple and inexpensive poin-
t-of-care tests improve diagnosis of vaginal infections in resource
constrained settings. Trop Med Int Health 2009; 14: 703–708.
29. Michel C-EC, Saison FG, Joshi H et al. Pitfalls of internet-accessible
diagnostic tests: inadequate performance of a CE-marked Chlamydia
test for home use. Sex Transm Infect 2009; 85: 187–189.
30. Pearson J. Point-of-care-testing and clinical governance. Clin Chem
Lab Med 2006; 44: 765–767.
31. Nissinen A, Strande´n P, Myllyus R et al. Point-of-care testing of
group A streptococcal antigen: performance evaluated by external
quality assessment. Eur J Clin Microbiol Infect Dis 2009; 28: 17–20.
32. Schimke I. Quality and timeliness in medical laboratory testing. Anal
Bioanal Chem 2009; 393: 1499–1504.
33. Mabey D, Peeling RW, Ustianowski A, Perkins MD. Diagnostics for
the developing world. Nat Rev Microbiol 2004; 2: 231–240.
34. Urdea M, Penny LA, Olmsted SS et al. Requirements for high impact
diagnostics in the developing world. Nature 2006; 444 (suppl 1): 73–
79.
35. Peters RPH, van Agtmael MA, Danner SA et al. New developments
in the diagnosis of bloodstream infections. Lancet Infect Dis 2004; 4:
751–760.
36. Wongsrichanalai C, Barcus MJ, Muth S et al. A review of malaria
diagnostic tools: microscopy and rapid diagnostic test (RDT). Am J
Trop Med Hyg 2007; 77 (suppl 6): 119–127.
37. Perkins MD, Bell DR. Working without a blindfold: the critical role
of diagnostics in malaria control. Malar J 2008; 7 (suppl 1): S5.
38. Green C, Huggett JF, Talbot E et al. Rapid diagnosis of tuberculosis
through the detection of mycobacterial DNA in urine by nucleic acid
ampliﬁcation methods. Lancet Infect Dis 2009; 9: 505–511.
39. Hazelton PR, Gelderblom HR. Electron microscopy for rapid diagno-
sis of infectious agents in emergent situations. Emerg Infect Dis 2003;
9: 294–303.
40. Dwarakanath S, Bruno JG, Shastry A et al. Quantum dot-antibody
and aptamer conjugates shift ﬂuorescence upon binding bacteria. Bio-
chem Biophys Res Commun 2004; 325: 739–743.
41. Shamah SM, Healy JM, Cload ST. Complex target SELEX. Acc Chem
Res 2008; 41: 130–138.
42. Ulrich H, Wrenger C. Disease-speciﬁc biomarker discovery by apta-
mers. Cytometry 2009; 75A: 727–733.
43. Kammila S, Das D, Bhatnagar PK et al. A rapid point of care immuno-
swab assay for SARS-CoV detection. J Virol Methods 2008; 152: 77–84.
44. Mayer G. The chemical biology of aptamers. Angew Chem Int Ed
2009; 48: 2672–2689.
45. Platt M, Rowe W, Wedge DC et al. Aptamer evolution for array-
based diagnostics. Anal Biochem 2009; 390: 203–205.
46. Chan CP-y, Cheung Y-c, Renneberg R, Seydack M. New trends in
immunoassays. Adv Biochem Eng/Biotechnol 2008; 109: 123–154.
47. Blicharz TM, Siqueira WL, Helmerhorst EJ et al. Fiber-optic micro-
sphere-based antibody array for the analysis of inﬂammatory cyto-
kines in saliva. Anal Chem 2009; 81: 2106–2114.
48. van Lieshout RML, van Domburg T, Saalmink M et al. Three-dimen-
sional ﬂow-through protein platform. Anal Chem 2009; 81: 5165–
5171.
49. Ohk SH, Koo OK, Sen T et al. Antibody-aptamer functionalized ﬁbre-
optic biosensor for speciﬁc detection of Listeria monocytogenes from
food. J Appl Microbiol 2010; doi:10.1111/j.1365-2672.2010.04709.x
50. Weile J, Knabbe C. Current applications and future trends of molec-
ular diagnostics in clinical bacteriology. Anal Bioanal Chem 2009; 394:
731–742.
51. Nougairede A, Ninove L, Zandotti C et al. Point of care strategy for
rapid diagnosis of novel A/H1N1 inﬂuenza virus. PLoS ONE 2010; 5:
e9215.
52. Bergeron MG, Ke D, Me´nard C et al. Rapid detection of Group B
streptococci in pregnant women at delivery. N Engl J Med 2000; 343:
175–179.
53. Tran NK, Wisner D, Albertson T et al. Quantitative point-of-care
pathogen in septicemia. Point Care 2008; 7: 107–110.
54. Dierkes C, Ehrenstein B, Siebig S et al. Clinical impact of a commer-
cially available multiplex PCR system for rapid detection of patho-
gens in patients with presumed sepsis. BMC Infect Dis 2009; 9: 126.
55. Westh H, Lisby G, Breysse F et al. Mutliplex real-time PCR and
blood culture for identiﬁcation of bloodstream pathogens in patients
with suspected sepsis. Clin Microbiol Infect 2009; 15: 544–551.
56. Lee HH, Dineva MA, Chua YL et al. Simple ampliﬁcation-based assay:
a nucleic acid-based point-of-care platform for HIV-1 testing. J Infect
Dis 2010; 201: S65–S71.
57. Jeong Y-J, Park K, Kim D-E. Isothermal DNA ampliﬁcation in vitro:
the helicase-dependent ampliﬁcation system. Cell Mol Life Sci 2009;
66: 3325–3336.
58. Mori Y, Notomi T. Loop-mediated isothermal ampliﬁcation (LAMP):
a rapid, accurate, and cost-effective diagnostic method for infectious
diseases. J Infect Chemother 2009; 15: 62–69.
59. Andresen D, von Nickish-Rosenegk M, Bier FF. Helicase-dependent
ampliﬁcation: use in OnChip ampliﬁcation and potential for point-of-
care diagnostics. Expert Rev Mol Diagn 2009; 9: 645–650.
60. Fang X, Liu Y, Kong J, Jiang X. Loop-mediated isothermal ampliﬁca-
tion integrated on microﬂuidic chips for point-of-care quantitative
detection of pathogens. Anal Chem 2010; 82: 3002–3006.
61. Miller MB, Tang Y-W. Basic concepts of microarrays and potential
applications in clinical microbiology. Clin Microbiol Rev 2009; 22: 611–
633.
62. Situma C, Hashimoto M, Soper SA. Merging microﬂuidics with
microarray-based bioassays. Biomol Eng 2006; 23: 213–231.
63. Mark D, Haeberle S, Roth G et al. Microﬂuidic lab-on-a-chip plat-
forms: requirements, characteristics and applications. Chem Soc Rev
2010; 39: 1153–1182.
64. Bergeron MG. Revolutionizing the practice of medicine through
rapid (< 1h) DNA-based diagnostics. Clin Invest Med 2008; 31: E265–
E271.
65. Brennan D, Justice J, Corbett B et al. Emerging optoﬂuidic technolo-
gies for point-of-care genetic analysis systems: a review. Anal Bioanal
Chem 2009; 395: 621–636.
66. Kiechle FL, Holland CA. Point-of-care testing and molecular diagnos-
tics: miniaturization required. Clin Lab Med 2009; 29: 555–560.
67. Ligler FS. Perspective on optical biosensors and integrated sensor
systems. Anal Chem 2009; 81: 519–526.
68. Siegrist J, Peytavi R, Bergeron MG, Madou M. Microﬂuidics for IVD
analysis: triumphs and hurdles of centrifugal platforms—Part 1:
molecular fundamentals. IVD Technol 2009; 15: 27–33.
69. Siegrist J, Peytavi R, Bergeron MG, Madou M. Microﬂuidics for IVD
analysis: triumphs and hurdles of centrifugal platforms—Part 2: Cen-
trifugal microﬂuidics. IVD Technol 2010; 16: 41–47.
70. Ehrmeyer SS, Laessig RH. Regulatory compliance for point-of-care
testing: 2009 United States perspective. Clin Lab Med 2009; 29: 463–
478.
71. Yager P, Domingo GJ, Gerdes J. Point-of-care diagnostics for global
health. Annu Rev Biomed Eng 2008; 10: 107–144.
72. Madou M, Zoval J, Jia G et al. Lab on a CD. Annu Rev Biomed Eng
2006; 8: 601–628.
73. Chin CD, Linder V, Sia SK. Lab-on-a-chip devices for global health:
past studies and future opportunities. Lab Chip 2007; 7: 41–57.
74. Myers FB, Lee LP. Innovations in optical microﬂuidic technologies
for point-of-care diagnostics. Lab Chip 2008; 8: 2015–2031.
1052 Clinical Microbiology and Infection, Volume 16 Number 8, August 2010 CMI
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1044–1053
75. Weigl B, Domingo G, LaBarre P, Gerlach J. Towards non- and mini-
mally instrumented, microﬂuidics-based diagnostic devices. Lab Chip
2008; 8: 1999–2014.
76. Carrilho E, Martinez AW, Whitesides GM. Understanding wax print-
ing: a simple micropatterning process for paper-based microﬂuidics.
Anal Chem 2009; 81: 7091–7095.
77. Qiu X, Thompson JA, Chen Z et al. Finger-actuated, self-contained
immunoassay cassettes. Biomed Microdevices 2009; 11: 1175–1186.
78. Nie Z, Nijhuis CA, Gong J et al. Electrochemical sensing in paper-
based microﬂuidic device. Lab Chip 2010; 10: 477–483.
79. Seng P, Drancourt M, Gouriet F et al. Ongoing revolution in bacteri-
ology: routine identiﬁcation of bacteria by matrix-assisted laser
desorption ionization time-of-ﬂight mass spectrometry. Clin Infect Dis
2009; 49: 543–551.
80. Christner M, Rohde H, Wolters M et al. Rapid identiﬁcation of
bacteria from positive blood culture bottles using MALDI-TOF
mass spectrometry ﬁngerprinting. J Clin Microbiol 2010; 48: 1584–1591.
81. Marinach-Patrice C, Fekkar A, Atanasova R et al. Rapid species diag-
nosis for invasive candidiasis using mass spectrometry. PLoS ONE
2010; 5: e8862.
82. Sauer S, Kliem M. Mass spectrometry tools for the classiﬁcation and
identiﬁcation of bacteria. Nat Rev Microbiol 2010; 8: 74–82.
83. Petrosino JF, Highlander S, Luna RA et al. Metagenomic pyrose-
quencing and microbial identiﬁcation. Clin Chem 2009; 55: 856–
866.
84. Tweardy DJ, Belmont JW. ‘Personalizing’ academic medicine: oppor-
tunities and challenges in implementing genomic proﬁling. Transl Res
2009; 154: 288–294.
85. Pettersson E, Lundeberg J, Ahmadian A. Generations of sequencing
technologies. Genomics 2009; 93: 105–111.
86. Xu M, Fujita D, Hanagata N. Perspectives and challenges of emerging
single-molecule DNA sequencing technologies. Small 2009; 5: 2638–
2649.
87. Metzker ML. Sequencing technologies—the next generation. Nat Rev
Genet 2010; 11: 31–46.
88. Calleja M, Nordstro¨m M, A´lvarez M et al. Highly sensitive polymer-
based cantilever-sensors for DNA detection. Ultramicroscopy 2005;
105: 215–222.
89. Ymeti A, Greve J, Lambeck PV et al. Fast, ultrasensitive virus detection
using a Young interferometer sensor. Nano Lett 2007; 7: 394–397.
90. A´lvarez M, Carrascosa LG, Zinoviev K et al. Biosensors based on
cantilevers. Methods Mol Biol 2009; 504: 51–71.
91. Piliarik M, Vaisocherova´ H, Homola J. Surface plasmon resonance
biosensing. Methods Mol Biol 2009; 503: 65–88.
92. Hiep HM, Saito M, Nakamura Y, Tamiya E. RNA aptamer-based
optical nanostructured sensor for highly sensitive and label-free
detection of antigen–antibody reactions. Anal Bioanal Chem 2010;
396: 2575–2581.
93. Hauck TS, Giri S, Gao Y, Chan WCW. Nanotechnology diagnostics
for infectious diseases prevalent in developing countries. Adv Drug
Deliv Rev 2010; 62: 438–448.
94. Kaittanis C, Santra S, Perez JM. Emerging nanotechnology-based
strategies for the identiﬁcation of microbial pathogenesis. Adv Drug
Deliv Rev 2010; 62: 408–423.
95. Lee WG, Kim Y-G, Chung BG et al. Nano/Microﬂuidics for diagnosis
of infectious diseases in developing countries. Adv Drug Deliv Rev
2010; 62: 449–457.
96. Tallury P, Malhotra A, Byrne LM, Santra S. Nanobioimaging and
sensing of infectious diseases. Adv Drug Deliv Rev 2010; 62: 424–437.
97. Lewandrowski K. Point-of-care testing: an overview and a look to
the future (circa 2009, United States). Clin Lab Med 2009; 29: 421–
432.
98. Brouqui P, Puro V, Fusco FM et al. Infection control in the manage-
ment of highly pathogenic infectious diseases: consensus from the
European Network of Infectious Disease. Lancet Infect Dis 2009; 9:
301–311.
99. Usdin M, Guillerm M, Calmy A. Patient needs and point-of-care
requirement for HIV load testing in resource-limited settings. J Infect
Dis 2010; 201: S73–S77.
100. Cunningham R, Jenks P, Northwood J et al. Effect on MRSA trans-
mission of rapid PCR testing of patients admitted to critical care. J
Hosp Infect 2007; 65: 24–28.
101. US. Food and Drug Administration. Medical device home use initiative.
Washington, DC: Center for Devices and Radiological Health. Avail-
able at: http://www.fda.gov/downloads/MedicalDevices/Productsand-
MedicalProcedures/HomeHealthandConsumer/HomeUseDevices/
UCM209056.pdf (last accessed 22 April 2010).
102. Kearns AJ, O’Mathu´na DP, Scott PA. Diagnostic self-testing: autono-
mous choices and relational responsibilities. Bioethics 2010; 24: 199–
207.
CMI Bissonnette and Bergeron Current and future technologies for POC diagnosis of infections 1053
ª2010 The Authors
Journal Compilation ª2010 European Society of Clinical Microbiology and Infectious Diseases, CMI, 16, 1044–1053
